These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28511567)

  • 21. The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.
    Jain N; O'Brien S
    Expert Rev Hematol; 2013 Oct; 6(5):575-86. PubMed ID: 24083594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Managing inadequate responses to frontline treatment of chronic myeloid leukemia: a case-based review.
    Bixby DL
    Cancer Treat Rev; 2013 May; 39(3):241-51. PubMed ID: 22818213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
    Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
    Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
    Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.
    Gomez-de-León A; Gómez-Almaguer D; Ruiz-Delgado GJ; Ruiz-Arguelles GJ
    Expert Rev Hematol; 2017 Sep; 10(9):809-819. PubMed ID: 28742419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
    Rea D; Mahon FX
    Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expanding options for front-line treatment in patients with newly diagnosed CML.
    Pinilla-Ibarz J; Flinn I
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):287-99. PubMed ID: 22487423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.
    Breccia M; Alimena G
    Expert Opin Pharmacother; 2011 Sep; 12(13):2075-87. PubMed ID: 21721847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
    Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
    Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.
    Heaney ML
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):502-8. PubMed ID: 25356574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications.
    Ritchie EK
    Leuk Lymphoma; 2019 May; 60(5):1116-1125. PubMed ID: 30481083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
    Francis S; Lucas C; Lane S; Wang L; Watmough S; Knight K; Bell J; Kaleel-Rahman M; Lee E; O'Brien D; Butt NM; Sadik W; De Soysa L; Seale JR; Salim R; Clark RE
    Leuk Res; 2013 Jul; 37(7):752-8. PubMed ID: 23618689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
    N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.
    Jiang Q; Liu ZC; Zhang SX; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1539-47. PubMed ID: 27085529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.